Clinical evaluation of cefatrizine (CFT) on respiratory infectious disease

Kotaro Oizumi, Akira Watanabe, Masako Sasaki, Sonoko Saito, Yukinori Yonemoto, Kiyoshi Konno

    Research output: Contribution to journalArticlepeer-review


    Antibacterial activities of cefatrizine (CFT) were examined. The growth of all 5 clinical isolates of Staphylococcus aureus was inhibited by the drug. About a half of 16 patient strains of Klebsiellapneumoniae were inhibited, but the remaining strains were not. None of 7 clinically isolated strains of Pseudomonas aeruginosa was sensitive to the drug. Clinical evaluation of cefatrizine was made on 8 patients with respiratory infectious diseases. In a patient with primary lung abscess, an excellent therapeutic effect was obtained by the oral administration of 2g daily dose of the drug. In 2 out of 4 patients with primary pneumonia, the therapeutic effect was good, but in the other two the responses were not satisfactory. Of 3 patients with secondary bacterial infections to underlying respiratory diseases, only a patient showed a good clinical and bacteriological response. The values of laboratory tests on kidney and liver functions remained in normal ranges after the administration of the drug, except for a patient in whom a moderately elevated S-GPT value was observed, probably because of co-existence of biliary tract infection.

    Original languageEnglish
    Pages (from-to)1729-1734
    Number of pages6
    Issue number9
    Publication statusPublished - 1976 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Clinical evaluation of cefatrizine (CFT) on respiratory infectious disease'. Together they form a unique fingerprint.

    Cite this